Application of N6 methyladenine (m6A) reading protein hnRNPA2B1 in diagnosis and treatment of disuse osteoporosis

Through the N6 methyladenine reading protein hnRNPA2B1 as a biomarker and target, it promotes osteoblast differentiation, solves the fracture risk of waste osteoporosis caused by long-term space flight, and provides new diagnostic and therapeutic means. Reduce side effects of drugs.

CN118914565APending Publication Date: 2024-11-08FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411046980.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing anti-osteoporosis measures have serious side effects, and the weightless environment caused by long-term space flight breaks the balance of bone reconstruction, increases the risk of fractures, and lacks effective molecular biological interventions.

Method used

The N6 methyladenine reading protein hnRNPA2B1 is used as a potential biomarker and target to promote osteoblast differentiation and enhance bone development, and is used to diagnose and treat waste osteoporosis.

Benefits of technology

Overexpression of hnRNPA2B1 can significantly promote osteoblast differentiation, alleviate osteogenic differentiation disorders in mechanical unloading environments, reduce bone loss, provide new diagnostic and therapeutic means, and alleviate drug side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914565A_ABST
    Figure CN118914565A_ABST
Patent Text Reader

Abstract

According to the application of the N6 methyladenine (m6A) reading protein hnRNPA2B1 in diagnosis and treatment of disuse osteoporosis, the mechanical unloading environment is researched through a 2D rotation model and a tail suspension hind limb unloading model, the hnRNPA2B1 is lowered in both in-vitro and in-vivo model osteoblasts under mechanical unloading, and bone loss under mechanical unloading is related to the hnRNPA2B1. In addition, the hnRNPA2B1 disclosed by the invention can promote the differentiation of osteoblasts, and the overexpression of the hnRNPA2B1 can effectively relieve the differentiation inhibition of the osteoblasts in a mechanical unloading environment. The hnRNPA2B1 has a potential clinical application value in the diagnosis and treatment of the disuse osteoporosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of molecular biomedical technology, in particular to N 6 Methyladenine (m 6 A) Application of the reader protein hnRNPA2B1 in the diagnosis and treatment of disuse osteoporosis. Background Art

[0002] Disuse osteoporosis (DOP) is a secondary osteoporosis that is common in patients who are bedridden for a long time and astronauts who are in a weightless state during long-term space flight missions. Their bones are in a state of unloading for a long time, the mechanical stimulation of the bones is reduced, and the bone mass loss is significant, with the greatest bone mass loss in the lower limbs. DOP can also cause a series of complications, such as increased risk of kidney stones and pathological fractures, which seriously threaten life and health. The existing anti-osteoporosis measures are mainly drug therapy and mechanical stimulation, which can effectively reduce the incidence of fractures in patients with osteoporosis. However, the main side effects of these drugs, such as osteonecrosis and hypercalcemia, can cause great harm to human health. Therefore, it is necessary to conduct in-depth research on the potential molecular targets of DOP to provide a scientific basis for the formulation of more effective intervention measures.

[0003] As a dynamic organ, bones maintain a balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation in bone homeostasis. The maintenance of bone homeostasis is regulated by multiple factors, including inflammation, nutrition, hormones, and mechanical stress. Long-term unloading can disrupt this balance. For example, mechanical unloading during long-term space flight can disrupt the balance of bone remodeling, reduce bone formation, lead to disuse osteoporosis, increase the risk of fractures, and seriously threaten the health of astronauts. It has been reported that dysfunctions such as osteoblast differentiation, proliferation, and apoptosis play a key role in disuse bone loss.

[0004] Heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) is a 6 A reading protein that plays a role in many biological processes. hnRNPA2B1 is mainly localized in the cell nucleus and participates in regulating the maturation, transport and metabolism of nuclear mRNA and promoting the processing and splicing of primary microRNA (miRNA).

[0005] With the vigorous development of my country's manned space program, long-term in-orbit flight will become the norm for Chinese astronauts. The weightless environment breaks the balance between bone formation and bone resorption during bone reconstruction, leading to continuous disuse bone loss in load-bearing bones, increasing the risk of fractures, cardiovascular hypercalcification, urinary stones and other diseases, and becoming one of the most important factors limiting long-term manned space missions and Mars exploration activities. Some pharmacological and non-pharmacological countermeasures have been proposed to address this issue, including physical exercise, dietary supplements and drug protection, but long-term and repeated use of drugs cannot avoid serious side effects. Considering longer space expeditions, it is particularly important to further clarify the molecular biological mechanism of disuse bone loss and find potential protective targets. Summary of the invention

[0006] In order to overcome the above technical problems, the object of the present invention is to provide N 6 Methyladenine (m 6 A) Application of the reader protein hnRNPA2B1 in the diagnosis and treatment of disuse osteoporosis. 6 A reader protein hnRNPA2B1 is a potential biomarker for disuse osteoporosis and a new target for improving disuse osteoporosis.

[0007] The technical solution adopted by the present invention is:

[0008] N 6 Methyladenine (m 6 A) Application of the reader protein hnRNPA2B1 in the diagnosis and treatment of disuse osteoporosis.

[0009] m 6 A reader protein hnRNPA2B1 is a potential biomarker for disuse osteoporosis and a new target for combating disuse osteoporosis.

[0010] hnRNPA2B1 upregulates the expression of Runx2, a key transcription factor for osteoblast differentiation, thereby enhancing osteoblast differentiation function and promoting bone development, thereby achieving the effect of combating disuse osteoporosis.

[0011] Knockdown of hnRNPA2B1 can significantly inhibit the differentiation ability of MC3T3-E1 cells.

[0012] Overexpression of hnRNPA2B1 can alleviate the osteogenic differentiation disorder caused by the 2D rotator.

[0013] Mechanical unloading environment, ① Cell level: Rotational model, a gravity research platform that simulates mechanical unloading of cells through ground equipment. It can rotate cell samples around an axis perpendicular to the gravity field. The rotation speed must be fast enough to achieve a state where the rotating system no longer senses the rapidly rotating gravity vector, thereby achieving the purpose of mechanical unloading effect. ② Animal level: Tail suspension hind limb unloading model. The tail suspension experiment is a method of simulating weightlessness, in which the tail of the experimental animal (such as a mouse) is suspended so that its body presents a posture similar to hind limb unloading, that is, the forelimbs are on the ground, the hind limbs are off the ground, and the body is at an angle of 30-60° to the horizontal plane. This posture simulates the mechanical unloading state under weightlessness by reducing the support force on certain parts of the animal's body, generating a downward acceleration.

[0014] Beneficial effects of the present invention:

[0015] The present invention studies the mechanical unloading environment through a 2D rotation model and a tail-suspension hindlimb unloading model. Under mechanical unloading, hnRNPA2B1 is downregulated in osteoblasts of both in vitro and in vivo models, and bone loss under mechanical unloading is related to hnRNPA2B1.

[0016] In addition, hnRNPA2B1 of the present invention can promote the differentiation of osteoblasts, and overexpression of hnRNPA2B1 can effectively alleviate the inhibition of osteoblast differentiation in a mechanical unloading environment.

[0017] hnRNPA2B1 has potential clinical application value in the diagnosis and treatment of disuse osteoporosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 Schematic diagram of hnRNPA2B1 expression levels at the cellular and animal levels under simulated weightlessness.

[0019] Figure 2 Schematic diagram of the effect of hnRNPA2B1 on osteoblast function.

[0020] Figure 3 Schematic diagram of hnRNPA2B1 rescuing osteoblast differentiation inhibition under simulated weightlessness. DETAILED DESCRIPTION

[0021] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0022] (A) Application of hnRNPA2B1 in the diagnosis of disuse osteoporosis.

[0023] The present invention constructs a deloading model at the cell and animal levels by using 2D rotator-treated preosteoblast MC3T3-E1 and mouse hind limb tail suspension (HLU). The protein samples from cultured mouse MC3T3-E1 cells were detected by Western blotting, and it was found that the expression of hnRNPA2B1 was reduced. Figure 1 a). In addition, immunohistochemical staining revealed that hnRNPA2B1 expression was reduced in the hind limb bones of tail-suspended mice ( Figure 1 b).

[0024] (B) Effect of hnRNPA2B1 on osteoblast differentiation function.

[0025] The hnRNPA2B1 overexpression vector pcDNA3.1(+)-hnRNPA2B1 and siRNA-hnRNPA2B1 were transfected into MC3T3-E1 cells, respectively. The expressions of differentiation indicators Runx2, Col1A1 and ALP were detected by Western blotting and qRT-PCR, and the effects on osteogenic differentiation were detected by alkaline phosphatase staining. The results showed that hnRNPA2B1 promoted osteoblast differentiation ( Figure 2 ac). The sequences of siRNA-hnRNPA2B1 are: sense: 5'-GGUGGCUUAAGCUUUGAAATT-3'; antisense: 5'-UUUCAAAGCUUAAGCCACCTT-3'.

[0026] (III) Effect of overexpression of hnRNPA2B1 on the differentiation function of unloaded MC3T3-E1 cells.

[0027] The hnRNPA2B1 overexpression vector pcDNA3.1(+)-hnRNPA2B1 was transfected into MC3T3-E1 cells, and the transfected cells were placed in a 2D rotator for 48 hours without loading. The effects on osteogenic differentiation were detected by qRT-PCR and Western blotting to detect the expression of differentiation indicators Runx2 and Col1A1. Figure 3 ab), showing that hnRNPA2B1 can rescue the inhibited differentiation function of unloaded MC3T3-E1 cells.

[0028] In the application of the drugs in (i), (ii) and (iii) above, the drugs include one or more pharmaceutically acceptable carriers, the carriers include diluents, binders, adsorption carriers, fillers and disintegrants; the drugs also include additives, the additives include stabilizers, bactericides, buffers, isotonic agents, chelating agents, pH control agents and surfactants.

[0029] m 6 A modified reader protein hnRNPA2B1 was significantly down-expressed in a cell unloading model (2D rotation MC3T3-E1 cells), suggesting that it may serve as a potential biomarker for disuse osteoporosis.

[0030] Knockdown of hnRNPA2B1 can significantly inhibit the differentiation ability of MC3T3-E1 cells, while overexpression of hnRNPA2B1 can significantly promote osteoblast differentiation. In addition, overexpression of hnRNPA2B1 can partially alleviate the osteogenic differentiation disorder caused by the 2D rotator, indicating its importance to osteogenic differentiation, providing a reference for the treatment of disuse osteoporosis.

[0031] The present invention conducts an in-depth and systematic study on the relationship between hnRNPA2B1 and disuse osteoporosis; based on the above findings, the expression level of hnRNPA2B1 can be used as a new biomarker to assist in the diagnosis of disuse osteoporosis, and can be used as a new target to combat disuse osteoporosis, which has good prospects for translational medicine.

Claims

1. N 6 Methyladenine (m 6 A) Application of the reader protein hnRNPA2B1 in the diagnosis and treatment of disuse osteoporosis.

2. The N according to claim 1 6 Methyladenine (m 6 A) Use of the reader protein hnRNPA2B1 in the diagnosis and treatment of disuse osteoporosis, characterized in that: m 6 A reader protein hnRNPA2B1 is a potential biomarker for disuse osteoporosis and a new target for combating disuse osteoporosis.

3. The N according to claim 1 6 Methyladenine (m 6 A) Use of the reader protein hnRNPA2B1 in the diagnosis and treatment of disuse osteoporosis, characterized in that: hnRNPA2B1 upregulates the expression of Runx2, a key transcription factor for osteoblast differentiation, thereby enhancing osteoblast differentiation function and promoting bone development, thereby achieving the effect of combating disuse osteoporosis.

4. The N according to claim 3 6 Methyladenine (m 6 A) Use of the reader protein hnRNPA2B1 in the diagnosis and treatment of disuse osteoporosis, characterized in that: Knockdown of hnRNPA2B1 can significantly inhibit the differentiation ability of MC3T3-E1 cells.

5. The N according to claim 3 6 Methyladenine (m 6 A) Use of the reader protein hnRNPA2B1 in the diagnosis and treatment of disuse osteoporosis, characterized in that: Overexpression of hnRNPA2B1 can alleviate the osteogenic differentiation disorder caused by the 2D rotator.